Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis

Li, 2020, Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med, 382, 1199, 10.1056/NEJMoa2001316 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Dong, 2020, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis, 20, 533, 10.1016/S1473-3099(20)30120-1 Peters, 2020, Transforming ORs into ICUs, N Engl J Med, 382, e52, 10.1056/NEJMc2010853 Phua, 2020, Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations, Lancet Respir Med, 8, 506, 10.1016/S2213-2600(20)30161-2 Ranney, 2020, Critical supply shortages - the need for ventilators and personal protective equipment during the covid-19 pandemic, N Engl J Med, 382, e41, 10.1056/NEJMp2006141 Truog, 2020, The toughest triage - allocating ventilators in a pandemic, N Engl J Med, 382, 1973, 10.1056/NEJMp2005689 Polack, 2020, Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine, N Engl J Med, 383, 2603, 10.1056/NEJMoa2034577 Baden, 2021, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N Engl J Med, 384, 403, 10.1056/NEJMoa2035389 Sadoff, 2021, Interim results of a phase 1-2a trial of Ad26.COV2.S covid-19 vaccine, N Engl J Med, 384, 1824, 10.1056/NEJMoa2034201 Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 Dagan, 2021, BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting, N Engl J Med, 384, 1412, 10.1056/NEJMoa2101765 Liu, 2020, Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis, CMAJ (Can Med Assoc J), 192, E734, 10.1503/cmaj.200647 Abdelrahman, 2021, Evaluation of the current therapeutic approaches for COVID-19: a systematic review and a meta-analysis, Front Pharmacol, 12, 607408, 10.3389/fphar.2021.607408 Gandhi, 2020, Mild or moderate covid-19, N Engl J Med, 383, 1757, 10.1056/NEJMcp2009249 World Health Organization, 2020 2020, 2020 Grein, 2020, Compassionate use of remdesivir for patients with severe covid-19, N Engl J Med, 382, 2327, 10.1056/NEJMoa2007016 Beigel, 2020, Remdesivir for the treatment of covid-19—preliminary report, N Engl J Med, 383, 993 Beigel, 2020, Remdesivir for the treatment of covid-19 - final report, N Engl J Med, 383, 1813, 10.1056/NEJMoa2007764 Kalil, 2021, Baricitinib plus remdesivir for hospitalized adults with covid-19, N Engl J Med, 384, 795, 10.1056/NEJMoa2031994 Wang, 2020, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 395, 1569, 10.1016/S0140-6736(20)31022-9 Abd-Elsalam, 2020, Hydroxychloroquine in the treatment of COVID-19: a multicenter randomized controlled study, Am J Trop Med Hyg, 103, 1635, 10.4269/ajtmh.20-0873 Cao, 2020, A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19, N Engl J Med, 382, 1787, 10.1056/NEJMoa2001282 Cavalcanti, 2020, Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19, N Engl J Med, 383, 2041, 10.1056/NEJMoa2019014 Chen, 2020, A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), PloS One, 15 Horby, 2020, Effect of hydroxychloroquine in hospitalized patients with covid-19, N Engl J Med, 383, 2030, 10.1056/NEJMoa2022926 Mitjà, 2020, Hydroxychloroquine for early treatment of adults with mild covid-19: a randomized-controlled trial, Clin Infect Dis Omrani, 2020, Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19, EClinicalMedicine, 29, 100645, 10.1016/j.eclinm.2020.100645 2020, Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 396, 1345, 10.1016/S0140-6736(20)32013-4 Lamontagne, 2021, A living WHO guideline on drugs to prevent covid-19, BMJ, 372, n526, 10.1136/bmj.n526 Siemieniuk, 2020, A living WHO guideline on drugs for covid-19, BMJ, 370, m3379 Rubin, 2020, FDA approval of remdesivir - a step in the right direction, N Engl J Med, 383, 2598, 10.1056/NEJMp2032369 Gao, 2020, Structure of the RNA-dependent RNA polymerase from COVID-19 virus, Science, 368, 779, 10.1126/science.abb7498 Gordon, 2020, The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus, J Biol Chem, 295, 4773, 10.1074/jbc.AC120.013056 Jorgensen, 2020, Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19, Pharmacotherapy, 40, 659, 10.1002/phar.2429 Norrie, 2020, Remdesivir for COVID-19: challenges of underpowered studies, Lancet, 395, 1525, 10.1016/S0140-6736(20)31023-0 McCreary, 2020, Efficacy of remdesivir in COVID-19, J Am Med Assoc, 324, 1041, 10.1001/jama.2020.16337 Cohen, 2020, “A very, very bad look” for remdesivir, Science, 370, 642, 10.1126/science.370.6517.642 Dyer, 2020, Covid-19: remdesivir has little or no impact on survival, WHO trial shows, BMJ, 371 World Health Organization, 2020 Jen, 2021, Evaluating clinical efficacy of antiviral therapy for COVID-19: a surrogate endpoint Approach, Infect Dis Ther, 1 Wu, 2014, Risk assessment of multistate progression of breast tumor with state-dependent genetic and environmental covariates, Risk Anal, 34, 367, 10.1111/risa.12116 Nachega, 2021, Addressing challenges to rolling out COVID-19 vaccines in African countries, Lancet Glob Heal, 9, e746, 10.1016/S2214-109X(21)00097-8 Vergara, 2021, Building public trust: a response to COVID-19 vaccine hesitancy predicament, J Public Health, 10.1093/pubmed/fdaa282 Schaffer DeRoo, 2020, Planning for a COVID-19 vaccination program, J Am Med Assoc, 323, 2458, 10.1001/jama.2020.8711 Dror, 2020, Vaccine hesitancy: the next challenge in the fight against COVID-19, Eur J Epidemiol, 35, 775, 10.1007/s10654-020-00671-y Sabino, 2021, Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence, Lancet, 397, 452, 10.1016/S0140-6736(21)00183-5 Ferguson, 2005, Strategies for containing an emerging influenza pandemic in Southeast Asia, Nature, 437, 209, 10.1038/nature04017 Moscona, 2005, Neuraminidase inhibitors for influenza, N Engl J Med, 353, 1363, 10.1056/NEJMra050740